[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f5oNyCJBZpIRUZzDrBFwq4JRFc9RpK-ndmPGjkBqTgiI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":47,"rows":54},"Helse Stavanger HF",[4],95,false,18,4,224803,3,79,[14,17,19,21,23,25,27,29],{"name":15,"count":16},"Coronary Artery Disease",5,{"name":18,"count":9},"Alzheimer Disease",{"name":20,"count":9},"Macular Holes",{"name":22,"count":9},"Dementia",{"name":24,"count":11},"Mild Cognitive Impairment",{"name":26,"count":11},"Heart Failure",{"name":28,"count":11},"Macular Hole",{"name":30,"count":11},"Myocardial Infarction",[32,37,42],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT05589974","Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy","2025-12-31","Verteporfin",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06362707","Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)","2028-01-01","Fasudil",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06020716","Antibiotics, Microbiology and Immunology in Children With Chronic Wet Cough - the AMIC Study","2028-04-30","Amoxicillin-Clavulanate 400 Mg-57 Mg\u002F5 mL Oral Powder for Reconstitution",[48,49,50,51,52,53],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[55,79,100,122,148,174,200,218,245,263,290,316,342,360,386,412,438,456,485,503,531,549],{"intervention":46,"totalTrials":56,"cells":57},1,{"EARLY_PHASE1":58,"PHASE1":61,"PHASE2":63,"PHASE3":65,"PHASE4":67,"NA":77},{"trials":59,"activeCount":60},[],0,{"trials":62,"activeCount":60},[],{"trials":64,"activeCount":60},[],{"trials":66,"activeCount":60},[],{"trials":68,"activeCount":56,"soonestReadout":45},[69],{"nctId":43,"briefTitle":44,"status":70,"phases":71,"primaryCompletion":45,"completion":45,"start":72,"enrollment":73,"conditions":74,"interventions":76},"RECRUITING",[52],"2023-08-16",350,[75],"Protracted Bacterial Bronchitis",[46],{"trials":78,"activeCount":60},[],{"intervention":41,"totalTrials":56,"cells":80},{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":94,"PHASE4":96,"NA":98},{"trials":82,"activeCount":60},[],{"trials":84,"activeCount":60},[],{"trials":86,"activeCount":56,"soonestReadout":40},[87],{"nctId":38,"briefTitle":39,"status":70,"phases":88,"primaryCompletion":40,"completion":40,"start":89,"enrollment":90,"conditions":91,"interventions":93},[50],"2024-08-01",200,[92,18],"Cognitive Decline, Mild",[41],{"trials":95,"activeCount":60},[],{"trials":97,"activeCount":60},[],{"trials":99,"activeCount":60},[],{"intervention":36,"totalTrials":56,"cells":101},{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":110,"NA":112},{"trials":103,"activeCount":60},[],{"trials":105,"activeCount":60},[],{"trials":107,"activeCount":60},[],{"trials":109,"activeCount":60},[],{"trials":111,"activeCount":60},[],{"trials":113,"activeCount":56,"soonestReadout":35},[114],{"nctId":33,"briefTitle":34,"status":70,"phases":115,"primaryCompletion":35,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":121},[],"2026-07-31","2022-10-01",50,[120],"Central Serous Chorioretinopathy",[36],{"intervention":123,"totalTrials":56,"cells":124},"Bupivacaine 5mg\u002Fml",{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":133,"NA":146},{"trials":126,"activeCount":60},[],{"trials":128,"activeCount":60},[],{"trials":130,"activeCount":60},[],{"trials":132,"activeCount":60},[],{"trials":134,"activeCount":60},[135],{"nctId":136,"briefTitle":137,"status":138,"phases":139,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":145},"NCT01677143","Pre-emptive Local Anaesthesia in Gynecological Laparoscopy","COMPLETED",[52],"2013-09","2013-02",24,[144],"Pain, Postoperative",[123],{"trials":147,"activeCount":60},[],{"intervention":149,"totalTrials":56,"cells":150},"Insulin dosing based on SMBG chart and education",{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":172},{"trials":152,"activeCount":60},[],{"trials":154,"activeCount":60},[],{"trials":156,"activeCount":60},[],{"trials":158,"activeCount":60},[],{"trials":160,"activeCount":60},[161],{"nctId":162,"briefTitle":163,"status":138,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":171},"NCT00284232","Metabolic Effects of Accurate Blood Sugar Results and Education in Type 1 Diabetes",[52],"2006-08","2006-12","2004-10",140,[170],"Diabetes Mellitus, Type 1",[149],{"trials":173,"activeCount":60},[],{"intervention":175,"totalTrials":56,"cells":176},"Rosuvastatin",{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":185,"NA":198},{"trials":178,"activeCount":60},[],{"trials":180,"activeCount":60},[],{"trials":182,"activeCount":60},[],{"trials":184,"activeCount":60},[],{"trials":186,"activeCount":60},[187],{"nctId":188,"briefTitle":189,"status":138,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT01382472","Microcirculation In Acute Coronary Syndromes",[52],"2016-12","2011-09",25,[195],"ST Elevation (STEMI) Myocardial Infarction",[175,197],"Simvastatin",{"trials":199,"activeCount":60},[],{"intervention":197,"totalTrials":56,"cells":201},{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":208,"PHASE4":210,"NA":216},{"trials":203,"activeCount":60},[],{"trials":205,"activeCount":60},[],{"trials":207,"activeCount":60},[],{"trials":209,"activeCount":60},[],{"trials":211,"activeCount":60},[212],{"nctId":188,"briefTitle":189,"status":138,"phases":213,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":214,"interventions":215},[52],[195],[175,197],{"trials":217,"activeCount":60},[],{"intervention":219,"totalTrials":56,"cells":220},"EPA \u002F DHA \u002F Alpha-Tocopherol",{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":241,"NA":243},{"trials":222,"activeCount":60},[],{"trials":224,"activeCount":60},[],{"trials":226,"activeCount":60},[],{"trials":228,"activeCount":60},[229],{"nctId":230,"briefTitle":231,"status":138,"phases":232,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":239},"NCT01422317","Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction",[51],"1997-12","2002-12","1995-09",300,[238,30],"Coronary Disease",[219,240],"Corn Oil \u002F Alpha-Tocopherol",{"trials":242,"activeCount":60},[],{"trials":244,"activeCount":60},[],{"intervention":240,"totalTrials":56,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":259,"NA":261},{"trials":248,"activeCount":60},[],{"trials":250,"activeCount":60},[],{"trials":252,"activeCount":60},[],{"trials":254,"activeCount":60},[255],{"nctId":230,"briefTitle":231,"status":138,"phases":256,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":257,"interventions":258},[51],[238,30],[219,240],{"trials":260,"activeCount":60},[],{"trials":262,"activeCount":60},[],{"intervention":264,"totalTrials":56,"cells":265},"Sildenafil",{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":286,"NA":288},{"trials":267,"activeCount":60},[],{"trials":269,"activeCount":60},[],{"trials":271,"activeCount":60},[],{"trials":273,"activeCount":60},[274],{"nctId":275,"briefTitle":276,"status":277,"phases":278,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":285},"NCT01616381","Sildenafil Versus Placebo in Chronic Heart Failure","UNKNOWN",[51],"2018-06","2019-12","2013-03",75,[26,284],"Pulmonary Hypertension",[264],{"trials":287,"activeCount":60},[],{"trials":289,"activeCount":60},[],{"intervention":291,"totalTrials":56,"cells":292},"Nab paclitaxel \u002F gemcitabine",{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":310,"PHASE4":312,"NA":314},{"trials":294,"activeCount":60},[],{"trials":296,"activeCount":60},[],{"trials":298,"activeCount":60},[299],{"nctId":300,"briefTitle":301,"status":138,"phases":302,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":309},"NCT02707159","Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients",[50],"2017-10","2019-01","2014-11",70,[308],"Metastatic Pancreatic Cancer",[291],{"trials":311,"activeCount":60},[],{"trials":313,"activeCount":60},[],{"trials":315,"activeCount":60},[],{"intervention":317,"totalTrials":56,"cells":318},"Renvela",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":320,"activeCount":60},[],{"trials":322,"activeCount":60},[],{"trials":324,"activeCount":60},[325],{"nctId":326,"briefTitle":327,"status":138,"phases":328,"primaryCompletion":329,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":334},"NCT01231438","Treatment of Early Stage Renal Failure With Active Vitamin D or a Phosphate Binder.",[50],"2011-03","2010-10",21,[333],"Kidney Failure",[317,335],"Etalpha",{"trials":337,"activeCount":60},[],{"trials":339,"activeCount":60},[],{"trials":341,"activeCount":60},[],{"intervention":335,"totalTrials":56,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":354,"PHASE4":356,"NA":358},{"trials":345,"activeCount":60},[],{"trials":347,"activeCount":60},[],{"trials":349,"activeCount":60},[350],{"nctId":326,"briefTitle":327,"status":138,"phases":351,"primaryCompletion":329,"completion":329,"start":330,"enrollment":331,"conditions":352,"interventions":353},[50],[333],[317,335],{"trials":355,"activeCount":60},[],{"trials":357,"activeCount":60},[],{"trials":359,"activeCount":60},[],{"intervention":361,"totalTrials":56,"cells":362},"Memantine",{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":380,"PHASE4":382,"NA":384},{"trials":364,"activeCount":60},[],{"trials":366,"activeCount":60},[],{"trials":368,"activeCount":60},[369],{"nctId":370,"briefTitle":371,"status":138,"phases":372,"primaryCompletion":373,"completion":374,"start":375,"enrollment":282,"conditions":376,"interventions":379},"NCT00630500","Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)",[50],"2009-02","2009-03","2006-02",[377,378],"Dementia Associated With Parkinson's Disease","Dementia With Lewy Bodies",[361],{"trials":381,"activeCount":60},[],{"trials":383,"activeCount":60},[],{"trials":385,"activeCount":60},[],{"intervention":387,"totalTrials":56,"cells":388},"Anakinra",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":406,"PHASE4":408,"NA":410},{"trials":390,"activeCount":60},[],{"trials":392,"activeCount":60},[],{"trials":394,"activeCount":60},[395],{"nctId":396,"briefTitle":397,"status":138,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":405},"NCT00683345","Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome",[50],"2010-04","2008-01",28,[403,404],"Fatigue","Primary Sjogren",[387],{"trials":407,"activeCount":60},[],{"trials":409,"activeCount":60},[],{"trials":411,"activeCount":60},[],{"intervention":413,"totalTrials":56,"cells":414},"Phenserine",{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":416,"activeCount":60},[],{"trials":418,"activeCount":60},[419],{"nctId":420,"briefTitle":421,"status":138,"phases":422,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":428},"NCT06774261","Phenserine on the Alzheimer's Treatment Horizon, Study 1",[49],"2025-12-01","2025-12-08","2025-02-01",16,[18,24],[413,429],"Donepezil",{"trials":431,"activeCount":60},[],{"trials":433,"activeCount":60},[],{"trials":435,"activeCount":60},[],{"trials":437,"activeCount":60},[],{"intervention":429,"totalTrials":56,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":448,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":441,"activeCount":60},[],{"trials":443,"activeCount":60},[444],{"nctId":420,"briefTitle":421,"status":138,"phases":445,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":446,"interventions":447},[49],[18,24],[413,429],{"trials":449,"activeCount":60},[],{"trials":451,"activeCount":60},[],{"trials":453,"activeCount":60},[],{"trials":455,"activeCount":60},[],{"intervention":457,"totalTrials":56,"cells":458},"botulinum toxin A",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":477,"PHASE3":479,"PHASE4":481,"NA":483},{"trials":460,"activeCount":60},[],{"trials":462,"activeCount":60},[463],{"nctId":464,"briefTitle":465,"status":466,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":60,"conditions":471,"interventions":475},"NCT03833063","Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression","WITHDRAWN",[49],"2019-12-31","2020-03-31","2019-05-01",[472,473,474],"Major Depressive Disorder","Major Depressive Episode","Treatment Resistant Depression",[457,476],"Placebos",{"trials":478,"activeCount":60},[],{"trials":480,"activeCount":60},[],{"trials":482,"activeCount":60},[],{"trials":484,"activeCount":60},[],{"intervention":476,"totalTrials":56,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":501},{"trials":488,"activeCount":60},[],{"trials":490,"activeCount":60},[491],{"nctId":464,"briefTitle":465,"status":466,"phases":492,"primaryCompletion":468,"completion":469,"start":470,"enrollment":60,"conditions":493,"interventions":494},[49],[472,473,474],[457,476],{"trials":496,"activeCount":60},[],{"trials":498,"activeCount":60},[],{"trials":500,"activeCount":60},[],{"trials":502,"activeCount":60},[],{"intervention":504,"totalTrials":56,"cells":505},"Acetylsalicylate",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":514,"NA":516},{"trials":507,"activeCount":60},[],{"trials":509,"activeCount":60},[],{"trials":511,"activeCount":60},[],{"trials":513,"activeCount":60},[],{"trials":515,"activeCount":60},[],{"trials":517,"activeCount":60},[518],{"nctId":519,"briefTitle":520,"status":277,"phases":521,"primaryCompletion":281,"completion":522,"start":523,"enrollment":118,"conditions":524,"interventions":529},"NCT01681615","Challenge Test for Acetylsalicylic Acid Hypersensitivity",[53],"2013-12","2012-09",[525,526,527,528],"Asthma Aspirin-sensitive","ASA Intolerant Asthma","Asthma, Aspirin-Induced","Asthma, Nasal Polyps, and Aspirin Intolerance",[504,530],"Isotonic NaCl",{"intervention":530,"totalTrials":56,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":539,"PHASE4":541,"NA":543},{"trials":534,"activeCount":60},[],{"trials":536,"activeCount":60},[],{"trials":538,"activeCount":60},[],{"trials":540,"activeCount":60},[],{"trials":542,"activeCount":60},[],{"trials":544,"activeCount":60},[545],{"nctId":519,"briefTitle":520,"status":277,"phases":546,"primaryCompletion":281,"completion":522,"start":523,"enrollment":118,"conditions":547,"interventions":548},[53],[525,526,527,528],[504,530],{"intervention":550,"totalTrials":56,"cells":551},"REBECCA-assisted intervention 1",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":553,"activeCount":60},[],{"trials":555,"activeCount":60},[],{"trials":557,"activeCount":60},[],{"trials":559,"activeCount":60},[],{"trials":561,"activeCount":60},[],{"trials":563,"activeCount":60},[564],{"nctId":565,"briefTitle":566,"status":277,"phases":567,"primaryCompletion":568,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":574},"NCT06120595","Intervention Study Based on Real-world Data to Improve Quality of Life After Breast Cancer Treatment, the REBECCA-2 Study",[53],"2023-11-01","2025-05-01","2022-11-01",81,[573],"Cancer Related Fatigue",[550]]